pioglitazone has been researched along with piperidines in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (35.48) | 29.6817 |
| 2010's | 36 (58.06) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Blackburn, G | 1 |
| Laws, A | 1 |
| Pospísilová, Y | 1 |
| Göke, B; Parhofer, KG | 1 |
| Moses, R | 1 |
| Gooch, B; Greco, S; Hale, PM; Hassman, DR; Jain, R; Jovanovic, L; Khutoryansky, N | 1 |
| Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
| Backman, JT; Jaakkola, T; Kajosaari, LI; Neuvonen, PJ | 1 |
| Vinik, AI | 1 |
| Choudhury, H; Harisudhan, T; Mullangi, R; Srinivas, NR; Venkatesh, P | 1 |
| Krentz, AJ | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Berry, C; Bourassa, MG | 1 |
| Akagami, T; Doi, T; Masuyama, T; Mori, Y; Naka, T; Ohyanagi, M; Sakoda, T; Tsujino, T | 1 |
| Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K | 2 |
| Argyrakopoulou, G; Doupis, J | 1 |
| Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L | 1 |
| Fleck, P; Karim, A; Laurent, A; Mekki, Q; Munsaka, M; Wann, E | 1 |
| Fleck, PR; Mekki, Q; Pratley, RE; Reusch, JE; Wilson, CA | 1 |
| Gumieniczek, A; Krzywdzińska, M; Nowak, M | 1 |
| Kalliokoski, A; Neuvonen, PJ; Niemi, M | 1 |
| Fleck, PR; Inzucchi, SE; Mekki, Q; Rosenstock, J; Seufert, J; Wilson, CA | 1 |
| Cersosimo, E; DeFronzo, RA; Triplitt, C | 1 |
| Kaneto, H; Kato, K; Kawashima, S; Matsuhisa, M; Matsuoka, TA; Shimomura, I; Tochino, Y; Yamamoto, K; Yamamoto, T | 1 |
| Chehab, MR; Gumieniczek, A; Komsta, L | 1 |
| Ueki, K | 1 |
| Hirayama, M; Hiroi, S; Itayasu, T; Kaku, K; Seino, Y | 1 |
| Bosi, E; Ellis, GC; Fleck, PR; Wilson, CA | 1 |
| Cederholm, J; Diamant, M; Eeg-Olofsson, K; Eliasson, B; Fleck, P; Möller-Goede, D; Smith, U; Taskinen, MR; Wilson, C | 1 |
| Burant, CF; DeFronzo, RA; Fleck, P; Mekki, Q; Pratley, RE; Wilson, C | 1 |
| Gumieniczek, A; Owczarek, B; Pawlikowska, B | 1 |
| Hirayama, M; Hiroi, S; Kaku, K; Miyata, Y; Seino, Y | 1 |
| Aswar, M; Bhutada, P; Kaulaskar, S; Otari, K; Rahigude, A | 1 |
| Bell, GI; Chong, AS; Grossman, EJ; Misawa, R; Park, SY; Tao, J; Wang, XJ; Witkowski, P; Yin, H; Zhong, R | 1 |
| Czogalla, J; Eguchi, A; Feldstein, AE; Fu, Y; Gerasimova, M; Kuczkowski, A; Masuda, T; Rose, MA; Scadeng, M; Vallon, V | 1 |
| Erowele, G; Ndefo, UA; Okoli, O | 1 |
| Diamant, M; Eliasson, B; Fleck, P; Mari, A; Möller-Goede, DL; Smith, U; Taskinen, MR; Tura, A; van Genugten, RE; Van Raalte, DH; Wilson, C | 1 |
| Balakrishnan, P; Bass, E; Bennett, WL; Bolen, S; Clark, JM; Gribble, MO; Kao, WH; Maruthur, NM; Sahu, A; Wilson, LM | 1 |
| Bettaieb, A; Cummings, BP; Graham, JL; Haj, FG; Havel, PJ; Stanhope, K | 1 |
| Aghaei, HN; Dehpour, AR; Ebrahimi, A; Gholizadeh, R; Gooshe, M; Mousavizadeh, K; Payandemehr, B; Rahimian, R; Varastehmoradi, B | 1 |
| Cai, Y; Lydic, TA; Olson, LK; Reid, GE; Turkette, T | 1 |
| Nagai, Y | 1 |
| Scheen, AJ | 1 |
| George, TM; Jennings, AS; Jennings, JS; Lovett, AJ | 1 |
| Hamamoto, S; Hashiramoto, M; Hirukawa, H; Kaku, K; Kaneto, H; Kimura, T; Kohara, K; Obata, A; Okauchi, S; Shimoda, M; Tawaramoto, K | 1 |
| Igeta, M; Kaku, K; Katou, M; Ohira, T; Sano, H | 1 |
| Qian, W; Tang, L; Xiao, Q; Xu, R; Yang, J | 1 |
| Bu, R; Gu, W; Han, P; Ji, Q; Jiang, Z; Lei, M; Li, C; Li, L; Li, W; Li, X; Li, Z; Liu, J; Liu, X; Liu, Y; Liu, Z; Lu, J; Lyu, X; Pan, C; Peng, Y; Qu, S; Shi, B; Song, Q; Xu, X; Xue, Y; Yan, L; Yang, J; Zeng, J; Zheng, B | 1 |
| Chan, J; Han, P; Hsieh, AT; Ji, Q; Li, C; Li, W; Lu, J; Pan, C; Yang, J; Zeng, J | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MA | 1 |
| Aoki, C; Aso, Y; Kasai, K; Kuroda, H; Sagara, M; Shimizu, M; Suzuki, K | 1 |
| Goricar, K; Janez, A; Jensterle, M | 1 |
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Amano, Y; Enya, K; Imai, M; Isono, O; Koumura, E; Matsukawa, J; Nagabukuro, H; Tohyama, K; Tsuchiya, S; Yasuno, H | 1 |
| Abdel-Aziz, O; Ayoub, BM | 1 |
| Badran, OM; Elghobashy, MR; Kelani, KM; Rezk, MR | 1 |
| Bombicz, M; Hegedűs, C; Juhász, B; Kiss, R; Kovács, D; Németh, J; Priksz, D; Szabó, AM; Szilvássy, Z; Varga, B; Wachal, Z | 1 |
| Chi, Y; Hemmingsen, B; Ipsen, EØ; Madsen, KS; Metzendorf, MI; Pedersen-Bjergaard, U; Richter, B | 1 |
| Chan, P; Lam, CWK; Tomlinson, B | 1 |
| Choi, SH; Chun, SW; Hur, KY; Jeong, IK; Kang, ES; Kim, HJ; Kim, SK; Noh, JH; Rhee, EJ | 1 |
14 review(s) available for pioglitazone and piperidines
| Article | Year |
|---|---|
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[News in oral antidiabetic therapy].
Topics: Administration, Oral; Carbamates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones | 2005 |
New oral agents for type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Troglitazone | 2007 |
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil | 2009 |
SLCO1B1 polymorphism and oral antidiabetic drugs.
Topics: Administration, Oral; Alleles; Carbamates; Cyclohexanes; Genotype; Haplotypes; Humans; Hypoglycemic Agents; Liver-Specific Organic Anion Transporter 1; Nateglinide; Organic Anion Transporters; Phenylalanine; Pioglitazone; Piperidines; Polymorphism, Genetic; Rosiglitazone; Thiazolidinediones | 2010 |
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipid Metabolism; Liver; Mice; Pioglitazone; Piperidines; Rats; Thiazolidinediones; Uracil | 2010 |
[A compounding agent of alogliptin and pioglitazone].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2011 |
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2014 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pharmacogenetics; Pioglitazone; Piperidines; Polymorphism, Genetic; Prediabetic State; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2014 |
Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2015 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Placebos; Randomized Controlled Trials as Topic; Risk | 2020 |
20 trial(s) available for pioglitazone and piperidines
| Article | Year |
|---|---|
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones | 2004 |
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Glucose; Capsules; Carbamates; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Female; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Pioglitazone; Piperidines; Substrate Specificity; Thiazolidinediones | 2006 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Topics: Adolescent; Adult; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Placebos; Thiazolidinediones; Uracil; Young Adult | 2009 |
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2010 |
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Topics: Asian People; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diet; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exercise; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2011 |
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2011 |
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Piperidines; Postprandial Period; Thiazolidinediones; Treatment Outcome; Uracil | 2012 |
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2012 |
Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2012 |
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2014 |
Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2015 |
Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone.
Topics: Adolescent; Adult; Algorithms; Biotransformation; Carbamates; Chemical Phenomena; Computational Biology; Cross-Over Studies; Drug Interactions; Expert Systems; Half-Life; Humans; Hypoglycemic Agents; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Biological; Pioglitazone; Piperidines; Software; Thiazolidinediones; Young Adult | 2015 |
[Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Topics: Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Safety; Thiazolidinediones; Uracil | 2015 |
Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Topics: Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Hong Kong; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Taiwan; Thiazolidinediones; Treatment Outcome; Uracil | 2017 |
Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
Topics: Aged; Alanine Transaminase; Blood Glucose; Body Mass Index; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; gamma-Glutamyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Piperidines; Uracil | 2017 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Meals; Metformin; Obesity; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prediabetic State; Prevalence; Slovenia; Thiazolidinediones; Uracil | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss | 2017 |
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Treatment Outcome; Uracil | 2022 |
28 other study(ies) available for pioglitazone and piperidines
| Article | Year |
|---|---|
Honing type 2 diabetes treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazoles; Thiazolidinediones | 2001 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human p
Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Piperidines; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2006 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss | 2008 |
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Bezafibrate; Cells, Cultured; DNA Primers; Dose-Response Relationship, Drug; Endothelin-1; Interleukin-18; Myocytes, Cardiac; NF-kappa B; Oligopeptides; Peptides, Cyclic; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Piperidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Thiazolidinediones | 2008 |
The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Eating; Enzyme Inhibitors; Hormones; Hyperinsulinism; Insulin; Lipids; Male; Mice; Mice, Obese; Pancreas; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Body Weight; Cell Degranulation; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Eating; Glucagon; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Mice; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2009 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones | 2009 |
Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Catalase; Diabetes Mellitus, Experimental; Glutathione; Glutathione Peroxidase; Hyperglycemia; Hypoglycemic Agents; Lipid Peroxidation; Lung; Male; Oxidative Stress; Pioglitazone; Piperidines; Rabbits; Reactive Nitrogen Species; Superoxide Dismutase; Thiazolidinediones; Tyrosine | 2009 |
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Body Weight; Deoxyguanosine; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Maf Transcription Factors, Large; Mice; Mice, Inbred C57BL; Pioglitazone; Piperidines; Receptors, Glucagon; Thiazolidinediones; Triglycerides; Uracil | 2011 |
Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia.
Topics: Aconitate Hydratase; Administration, Oral; Alloxan; Animals; Blood Glucose; Body Weight; Carbamates; Enzyme Activation; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Lipid Peroxidation; Male; Oxidative Stress; Pioglitazone; Piperidines; Rabbits; Reactive Nitrogen Species; Thiazolidinediones | 2011 |
Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide.
Topics: Animals; Antioxidants; Aqueous Humor; Carbamates; Diabetes Mellitus, Experimental; Glutathione Peroxidase; Hyperglycemia; Hypoglycemic Agents; Lipid Peroxidation; Male; Oxidative Stress; Pioglitazone; Piperidines; Rabbits; Thiazolidinediones | 2012 |
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Donepezil; Estrogen Antagonists; Fat Emulsions, Intravenous; Flavanones; Glutathione; Hypoglycemic Agents; Indans; Lipid Peroxidation; Male; Memory Disorders; Nitric Oxide; Parasympathetic Nervous System; Pioglitazone; Piperidines; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Thiazolidinediones | 2012 |
Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Synergism; Female; Gene Expression; Genes, Reporter; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Insulin-Secreting Cells; Luciferases; Luminescent Measurements; Male; Mice; Pioglitazone; Piperidines; Promoter Regions, Genetic; Regeneration; Sirolimus; Streptozocin; Tacrolimus; Thiazolidinediones; Uracil | 2013 |
Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Eating; Male; Mice; Pioglitazone; Piperidines; PPAR gamma; Thiazolidinediones; Uracil; Water-Electrolyte Balance | 2014 |
Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Eating; Humans; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Piperidines; Rats; Thiazolidinediones; Uracil | 2014 |
Involvement of PPAR receptors in the anticonvulsant effects of a cannabinoid agonist, WIN 55,212-2.
Topics: Anilides; Animals; Anticonvulsants; Benzoxazines; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Male; Mice; Morpholines; Naphthalenes; Oxazoles; Pentylenetetrazole; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Seizures; Thiazolidinediones; Tyrosine | 2015 |
Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Islets of Langerhans; Lipid Metabolism; Male; Pioglitazone; Piperidines; Prediabetic State; Rats; Rats, Zucker; Thiazolidinediones; Uracil | 2015 |
[Fixed-dose combination].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil | 2015 |
Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy".
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Goals; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome | 2015 |
Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Insulin Receptor Substrate Proteins; Insulin-Secreting Cells; Male; Mice; Pioglitazone; Piperidines; PPAR gamma; Thiazolidinediones; Uracil | 2015 |
Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine).
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Glipizide; Guanidines; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Hypoglycemic Agents; Liver; Liver Cirrhosis; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Pioglitazone; Piperidines; Thiazolidinediones; Treatment Outcome; Uracil | 2018 |
A guide for using experimental design in chromatographic method development: applied to the analysis of selected anti-diabetic pharmaceutical combinations.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Drug Combinations; Equipment Design; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Reference Standards; Reproducibility of Results; Solutions; Tablets; Thiazolidinediones; Uracil | 2016 |
Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study.
Topics: Chromatography, Liquid; Humans; Linear Models; Pioglitazone; Piperidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Uracil | 2019 |
Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Electroretinography; Glyburide; Humans; Hydroxamic Acids; Hypoglycemic Agents; Insulin; Male; Metformin; Molecular Structure; Oximes; Pioglitazone; Piperidines; Protective Agents; Rats; Rats, Wistar; Retina | 2020 |
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazolidinediones; Uracil | 2022 |